N. van der Meer

Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel

R. Mathijssen, R. de Wit, P. Hamberg, 2017, Oncotarget.

Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study

A. Bergman, R. Mathijssen, A. T. Ten Tije, 2016, Clinical Cancer Research.

The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: results of the randomised controlled phase 2 BELOB trial.

M. J. van den Bent, M. Taphoorn, J. Reijneveld, 2015, European journal of cancer.

Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases: the CHARISMA randomized multicenter clinical trial

C. Dejong, R. van Hillegersberg, C. Punt, 2015, BMC Cancer.

The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer.

A. Bergman, R. Mathijssen, R. de Wit, 2015, European journal of cancer.

Influence of Enzalutamide on Cabazitaxel Pharmacokinetics: a Drug–Drug Interaction Study in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients

R. Mathijssen, P. de Bruijn, R. de Wit, 2017, Clinical Cancer Research.

Neo-adjuvant chemotherapy followed by surgery versus surgery alone in high-risk patients with resectable colorectal liver metastases: the CHARISMA randomized multicenter clinical trial

C. Dejong, R. van Hillegersberg, C. Punt, 2015, BMC Cancer.